On December 2, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Cipla Ltd. (hereinafter referred to as " Cipla ") reached an exclusive license and supply agreement of a neonatal pharmaceutical product (hereinafter referred to as "the product"). Under the terms of the agreement, Beimei will be responsible for the registration and commercialization of the product in China.

The product is used for the prevention and treatment of hemorrhagic disease of newborn (HDN), and will be filed in China as an exclusive imported and child-specific medication. The product is a pre-filled, ready-to-use injection with the convenient and accurate administration designed for newborns. Meanwhile, compared with existing domestic products, the product does not contain the ingredients prohibited for use in infants and young children, therefore there is no such related safety risks. Since there is no same or similar products approved in China, it’s expected that the product will become the first child-specific medication approved for treating the HDN.

HDN is a bleeding disease caused by the lack of the active ingredients contained in the product. Clinical experts give a high degree of recommendation in the guidelines that it is a routine clinical process to give newborns this type of product to prevent bleeding after birth. In recent years, thanks to the routine prevention, the incidence rate of HDN has been significantly reduced. Currently, there are more than ten million newborns born in China every year. As the special drug for newborns, the product can effectively meet the drug demand of neonatal population in China, and alleviate the pain point of insufficient child-specific medication. Meanwhile, the product can also facilitate a more normative and universal prevention of HDN in the future.

The further cooperation with Cipla help Beimei to extend the neonatal product line. Beimei will continue to layout and enrich the neonatal pipeline, and expand it to be the advantageous portfolio in the future.

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets.

Cipla is ranked 3rd largest in pharma in India (IQVIA MAT March’ 22), 3rd largest in the pharma private market in South Africa (IQVIA MAT March’22), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For additional information, please visit https://www.cipla.com

About Beimei

Beimei pharmaceutical focuses on the field of pediatric prescription medicines, headquartered in Shenzhen, China, incorporating R&D, global licensing, manufacture, marketing and distribution, and has more than 30 pediatric products in its portfolio and pipeline, covering the respiratory system, anti-infection (antibacterial), nervous system, digestive system, endocrinology, ENT and other fields.

Beimei Pharmaceutical has established long-term partnerships with companies such as Hetero, Cipla, EMP, Deva, Dr Reddy, LTS, Med Pharma, Synthon, NTC, etc., and completed over 100 million RMB series A and series B/B+ financing, which will further support Beimei to be a pioneer in Chinese pediatric field to meet the clinically unmet demand and provide Chinese pediatric patients with products that are with high-quality, good tasting and can be accurately administrated. For additional information, please visit http://www.beimeiyaoye.com